This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The trial results should allow the company to ask the FDA for approval of its vaccine in younger children, just as Pfizer nears a crucial decision for its shot in 5- to 11-year olds.
The vaccine didn’t spur a strong enough immuneresponse against a particular flu strain in a Phase 3 trial, leading the companies to ponder adjustments.
Data from a small Phase 1 trial showed the biotech's vaccine spurred immuneresponses to four common strains, although they didn't appear significantly greater than an already available shot from Sanofi.
Syros Pharmaceuticals announced that its cancer drug tamibarotene failed to meet its primary endpoint in the SELECT-MDS-1 Phase III trial. The placebo-controlled SELECT-MDS-1 trial involved 190 patients with complete response rate (CRR) being the study’s primary endpoint. percent and 18.8
The pharma said its latest shot, which covers 21 strains of bacteria, cleared two Phase 3 trials and in some cases spurred a stronger immuneresponse than Pfizer’s Prevnar 20.
Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immuneresponse, according to results from a Phase 1 clinical trial released today.
The Phase IIa trial (NCT05734040) in Australia will see a potential 500 volunteers given OVX836 in combination with quadrivalent influenza vaccines (QIVs). The developer has tested OVX836 in four completed clinical trials. The aim of the latest ongoing trial is to evaluate the vaccine in a larger and more diverse population.
A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immuneresponse, although the study was too small to produce conclusive findings, particularly on safety. In the phase 1 part of the trial, participants received one component of the two-part vaccine.
The COVID-19 vaccine candidate developed by Sanofi and GlaxoSmithKline hit a snag that will delay the launch of a Phase III study due to an insufficient immuneresponse in older trial patients.
FDA greenlit the restart of AstraZeneca’s Phase III COVID-19 vaccine trial, the company said the preventative medication boosts immuneresponses in older and younger adults against the novel coronavirus. Days after the U.S.
The findings, which were disclosed in a press release without specific data, are the first immuneresponse results in humans for the reformulated shot targeting the BA.4 5 substrains.
Building on this history of success, Novocure recently revealed promising Phase III results from the PANOVA-3 clinical trial, marking a significant milestone in pancreatic cancer treatment. Novocure’s broader pipeline underscores the versatility of TTFields therapy.
The company’s shot sparked a strong enough immuneresponse against only one of two groups of influenza strains it was tested against in a closely watched Phase 3 trial.
With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world. One of the biggest hurdles in developing new therapies is recruiting diverse patients for clinical trials.
Worrisome immuneresponses had led the FDA to halt Solid's study. Now, the agency will permit Solid to continue after the biotech made adjustments to its manufacturing and patient enrollment procedures.
With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world. One of the biggest hurdles in developing new therapies is recruiting diverse patients for clinical trials.
Inhaled delivery of a formulation of a key protein involved in the immuneresponse – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.
A new HIV vaccine from Scripps Research has shown a significantly improved ability to neutralize the virus in preclinical tests, and it will soon be studied in healthy people who volunteer to participate in clinical trials.
The vaccine elicited a robust immuneresponse against several variants in registrational trials conducted when the Omicron variant of the virus was dominant. These trials comprised the Phase III VAT08 Stage 2 trial analysing initial efficacy and two other immunogenicity trials.
Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. One candidate – mRNA-1644 – has already shown its potential in an earlier phase 1 trial (IAVI G001) run in the US.
The mRNA-4157/V940 has been designed to stimulate an immuneresponse by producing T-cell responses depending on the mutational signature of a patient's tumour. The company said that the data from the ongoing Phase II trial will be reported in the fourth quarter of this year.
It can suppress Th2 immuneresponses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). This blocks a cascade of responses that are induced by interleukin-25 (IL-25), a critical cytokine which is classified as ‘alarmin’.
Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immuneresponse in the elderly, saying clinical trials showed an insufficient immuneresponse in older people.
There are many hypothesized causes that may co-exist in the same patient, such as persistent virus or antigens, reactivation of other viruses, uncontrolled immuneresponses, damage to a wide range of organs and tissues, and injury to blood vessels and abnormal blood clotting. The first trial will begin enrolling in July 2023.
Additionally, the immunogenicity of biosimilars, which is the ability of the drug to trigger an immuneresponse, can be highly variable and impact the safety and efficacy of the drug. Robust Clinical Trial Design : Clinical trials for biosimilars should be designed to demonstrate equivalence or non-inferiority to the reference product.
A nasal delivery method will also produce an immuneresponse at the point where the virus enters the body. The company announced a phase 1 trial is beginning of its nasal spray vaccine just as scientists in the UK said they are considering a similar approach.
A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immuneresponses in early and mid-stage trials.
A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. A non-temperature stable form of the candidate previously had been tested in several clinical trials.
Peer-reviewed / Randomised Controlled Trial / People Randomised, phase 2 trial of COVID-19 booster vaccines finds seven increase immunity when given 10-12 weeks after two doses of Oxford-AstraZeneca, and six increase immunity following two doses of Pfizer-BioNTech. UK trial involving 2,878 adults […].
Once introduced into the human body, the protein-making machinery uses this genetic material in our cells to churn out the coronavirus “spike protein,” triggering an immuneresponse. Another consideration is that while in traditional vaccine development, clinical trials are carried out in sequence. Then there are the finances.
The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immuneresponse and good safety profile. A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa.
Early results from the Phase 1/2 trial show that the vaccine is well-tolerated and induces strong immuneresponses, potentially paving the way for a more convenient approach to respiratory virus prevention.
Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immuneresponses in a phase 1 trial. . The post Altimmune ditches nasal COVID vaccine on weak trial data appeared first on.
Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immuneresponses to lethal infections. Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis.
The company posted an interim analysis of its Phase I/IIa trial that showed a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.
A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. The post Imugene HER2 vaccine hits target in stomach cancer trial appeared first on.
The CDC says “neither the recently authorized and recommended vaccines nor the other COVID-19 vaccines currently in clinical trials in the United States can cause you to test positive on viral tests , which are used to see if you have a current infection.? Plus, clinical trial settings aren’t always the same as real-world settings.
Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. This marks the second time one of Janssen’s HIV vaccines failed after another showed disappointing results in the Phase IIb Imbokodo trial in August 2021.
Exscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) last year, and now says it has started testing of the first AI candidate for immuno-oncology. . The post Exscientia starts trials of first AI-derived cancer immunotherapy appeared first on.
AstraZeneca may have tried a positive spin on the trial mistake that led to the accidental discovery of the low dose COVID-19 vaccine regime with the highest efficacy– but the revelation has drawn a mixed response from commentators.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content